Kyowa Kirin Co., Ltd. · TSE:4151
Kyowa Kirin — Corporate Update (March 2026)
7 slides from Kyowa Kirin's corporate update, Mar 4, 2026
Slide 1: Rocatinlimab Clinical Program Discontinuation
Rocatinlimab Clinical Program Discontinuation March 4th , 2026 Representative Director, Chairman, and Chief Executive Officer Masashi Miyamoto Representative Director, President, and Chief Operating Officer Abdul Mullick Director, Executive Vice President, and Chief Medical Officer Takeyoshi Yamashi
Slide 2: Overview of Today's Presentation
Overview of Today’s Presentation ◼ In late February, updated safety information from the global rocatinlimab clinical program, including the Phase 3 ROCKET program for moderate-to-severe atopic dermatitis was provided ◼ Following the planned joint safety evaluation meeting convened based on the late
Slide 3: Timeline of Events
Timeline of Events September 2025: Safety assessment of malignancies, including one case of Kaposi's sarcoma, showed no causal relationship with rocatinlimab January 2026: Rocatinlimab's benefit-risk assessment confirmed a favorable profile Late February 2026: Following the Joint Safety Assessment C
Slide 4: Future Actions
Future Actions ◼ Clinical trial investigators and regulatory bodies are currently being informed ◼ All clinical trials will be formally terminated after participating patients complete their safety follow-up ◼ Kyowa Kirin and Amgen will collaborate to conduct a comprehensive data analysis and provid
Slide 5: Impact on Business Performance
Impact on Business Performance • Short-term profit increase due to elimination of SG&A and R&D expenses related to rocatinlimab • Certain negative profit impact expected in the medium to long term ◼ Estimated Impact on Core Operating Profit ⚫ 2026 : Approx. +¥20～30 billion ⚫ 2027 : Approx. +¥30 bill
Slide 6: Impact on Mid- to Long-term Financial Targets and Future Management Policy
Impact on Mid- to Long-term Financial Targets and Future Management Policy ◼ No changes to the mid- to long-term financial targets announced in “Vision 2030 and beyond : Our Growth Story" published on February 9, 2026. These remain the targets we aim to achieve. ◼ Leveraging the following growth dri
Slide 7: Contact for Inquiries Regarding This Material
- Contact for Inquiries Regarding This Material - Kyowa Kirin Co., Ltd. Corporate Communications Department IR & PR Group 03-5205-7206 / ir@kyowakirin.com